TD Cowen analyst Joseph Thome has maintained their bullish stance on UTHR stock, giving a Buy rating on February 11.
Joseph Thome’s rating is based on several key factors. United Therapeutics reported Q4 revenues that aligned with market expectations, bolstered by strong performances from Remodulin and Unituxin. Although Tyvaso’s Q4 numbers fell short of consensus due to adjustments in gross-to-net (GTN) pricing, the company is working towards securing favorable contracts with payors, which should stabilize GTN levels and support future growth.
Moreover, the management’s confidence in the long-term potential of the treprostinil business, along with promising developments in the PH-ILD prescriber population, suggests a positive outlook. The anticipated Phase III IPF data in the latter half of 2025 presents a significant opportunity, with the potential to drive the stock price higher. Additionally, ongoing xenotransplantation efforts are progressing well, indicating further growth prospects. These factors collectively contribute to the Buy rating, highlighting an attractive risk-reward profile for investors.
In another report released on February 11, Leerink Partners also reiterated a Buy rating on the stock with a $430.00 price target.